Skip to main content
. 2018 Oct 15;2018(10):CD007927. doi: 10.1002/14651858.CD007927.pub4

2.7. Analysis.

2.7

Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 7 Toxicity: grade 3 or 4 thrombocytopaenia.